IFRS 2 Equity-Settled Share-Based Payments: Grant Date Fair Value Measurement

Share-based payment transactions are a common way for companies to compensate employees, directors, and other parties. When these payments involve issuing equity instruments, such as shares or share options, they fall under the purview of IFRS 2 Share-Based Payment. A cornerstone of accounting for these 'equity-settled' schemes is their measurement at fair value on a specific date: the grant date.

The Significance of Grant Date Fair Value

Under IFRS 2, the fundamental principle for equity-settled share-based payments is to measure them at their fair value at the date they are granted. This means the compensation expense recognised over the vesting period is based on the value determined on this initial date, and this value is not subsequently re-measured. Why is the grant date so critical? It represents the point when the company and the recipient agree on the terms and conditions of the award, establishing the initial economic value of the instruments being granted.

Using the grant date fair value ensures consistency and avoids the volatility that would arise from continuous re-measurement based on fluctuating market prices. It provides a reliable starting point for allocating the expense over the service period, reflecting the value of the goods or services received in exchange for the equity instruments.

How Fair Value is Determined at Grant Date

Determining the fair value at grant date depends on the nature of the equity instrument being granted:

For Shares

If a company grants shares, and those shares are actively traded, their fair value is simply the observable market price of a similar share on the grant date. If there are any restrictions on the shares (e.g., they cannot be traded for a certain period), this restriction should be factored into the valuation, typically resulting in a discount.

For Share Options

Share options are more complex because they are not simply shares. Their value depends on future events. Therefore, their fair value is typically determined using an option pricing model, such as the Black-Scholes-Merton formula or a binomial model. These models require several key inputs:

1. **Share Price:** The current market price of the company's shares at the grant date.

2. **Exercise Price:** The price at which the option holder can purchase the shares.

3. **Expected Volatility:** A measure of how much the share price is expected to fluctuate over the option's life. This is a crucial and often challenging input to estimate.

4. **Expected Life of the Option:** The period over which the option is expected to be outstanding, considering exercise patterns and contractual terms.

5. **Expected Dividends:** Any anticipated dividends over the option's life, as these reduce the value of a call option.

6. **Risk-Free Interest Rate:** The interest rate for a risk-free asset (like government bonds) with a maturity similar to the option's expected life.

All these inputs reflect expectations at the grant date. Market vesting conditions (e.g., achieving a certain share price target) are incorporated directly into the fair value measurement itself, as they affect the probability of exercise and thus the option's value.

The Importance of Accurate Valuation

Accurately measuring the grant date fair value is paramount for compliance with IFRS 2 and for providing transparent financial reporting. It directly impacts the amount of compensation expense recognised in the profit or loss over the vesting period. Actuarial expertise, particularly in estimating inputs like expected volatility and expected life, plays a vital role in ensuring these valuations are robust and reliable. Once established, this grant date fair value forms the basis for all subsequent accounting for that specific equity-settled share-based payment award.